Therapeutic outlook for Castleman’s disease: prospects for the next decade

References

• Castleman B, Towne VW. CASE records of the Massachusetts General Hospital. Weekly clinicopathological exercises: case 40011. N Engl J Med. 1954;250:26–30. [PubMed:13111435].
   Google Scholar
• Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–830. [PubMed:13356266].
   Google Scholar
• Frizzera G, Banks PM, Massarelli G, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Pathological findings in 15 patients. Am J Surg Pathol. 1983;7:211–231. [PubMed:6837832].
   Google Scholar
• Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43:698–704. [PubMed:15764213].
   Google Scholar
• Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128:657–662. [PubMed:9537940].
   Google Scholar
• Talat N, Schulte KM. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16:1316–1324. [PubMed:21765191].
   Google Scholar
• Kawabata H, Kadowaki N, Nishikori M, et al. Clinical features and treatment of multicentric Castleman’s disease: a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop. 2013;53:69–77. [PubMed:23801137].
   Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989;74:1360–1367. [PubMed:2788466].
   Google Scholar
• Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman’s disease like symptoms emerged in IL-6 transgenic mice. Cytokine. 2002;20:304–311. [PubMed:12633573].
   Google Scholar
• Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61–67. [PubMed:8924253].
   Google Scholar
• Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–1412. [PubMed:10666218].
   Google Scholar
• Cesarman E. The role of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Recent Results Cancer Res. 2002;159:27–37. [PubMed:11785841].
   Google Scholar
• Ascoli V, Sirianni MC, Mezzaroma I, et al. Human herpesvirus-8 in lymphomatous and nonlymphomatous body cavity effusions developing in Kaposi’s sarcoma and multicentric Castleman’s disease. Ann Diagn Pathol. 1999;3:357–363. [PubMed:10594287].
   Google Scholar
• Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16:236–246. [PubMed:19546611].
   Google Scholar
• Fajgenbaum DC, van Rhee F. Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123:2924–2933. [PubMed:24622327].
   Google Scholar
• Fajgenbaum DC, Ruth JR, Kelleher D, et al. The collaborative network approach: a new framework to accelerate Castleman’s disease and other rare disease research. Lancet Haematol. 2016;3:e150–2. [PubMed:27063967].
   Google Scholar
• Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017. [PubMed: 28087540].
   Google Scholar
• Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg. 2012;255:677–684. [PubMed:22367441].
   Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–2632. [PubMed:15998837].
   Google Scholar
• van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol. 2010;28:3701–3708. [PubMed:20625121].
   Google Scholar
• Nicholas J, Ruvolo VR, Burns WH, et al. Kaposi’s sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med. 1997;3:287–292. [PubMed:9055855].
   Google Scholar
• Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and without HIV infection. N Engl J Med. 1995;332:1181–1185. [PubMed:7700310].
   Google Scholar
• Bhutani M, Polizzotto MN, Uldrick TS, et al. Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. Semin Oncol. 2015;42:223–246. [PubMed:25843728].
   Google Scholar
• Hassman LM, Ellison TJ, Kedes DH. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest. 2011;121:752–768. [PubMed:21245574].
   Google Scholar
• Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97:2130–2136. [PubMed:11264181].
   Google Scholar
• Mori Y, Nishimoto N, Ohno M, et al. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J Med Virol. 2000;61:332–335. [PubMed:10861641].
   Google Scholar
• Brousset P, Cesarman E, Meggetto F, et al. Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi’s sarcoma and lymphoid cells of multicentric Castleman’s disease. Hum Pathol. 2001;32:95–100. [PubMed:11172301].
   Google Scholar
• Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman’s disease. Blood. 1991;78:2923–2930. [PubMed:1954381].
   Google Scholar
• Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol. 2000;156:743–749. [PubMed:10702388].
   Google Scholar
• Staskus KA, Sun R, Miller G, et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. J Virol. 1999;73:4181–4187. [PubMed:10196314].
   Google Scholar
• Cannon JS, Nicholas J, Orenstein JM, et al. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis. 1999;180:824–828. [PubMed:10438372].
   Google Scholar
• Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol. 1997;151:1517–1522. [PubMed:9403701].
   Google Scholar
• Aoki Y, Narazaki M, Kishimoto T, et al. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. Blood. 2001;98:3042–3049. [PubMed:11698289].
   Google Scholar
• Chow D, He X, Snow AL, et al. Structure of an extracellular gp130 cytokine receptor signaling complex. Science. 2001;291:2150–2155. [PubMed:11251120].
   Google Scholar
• Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93:4034–4043. [PubMed:10361100].
   Google Scholar
• Burger R, Neipel F, Fleckenstein B, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood. 1998;91:1858–1863. [PubMed:9490667].
   Google Scholar
• Song J, Ohkura T, Sugimoto M, et al. Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line. J Med Virol. 2002;68:404–411. [PubMed: 12226829].
   Google Scholar
• Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman’s disease. Br J Haematol. 1999;104:482–485. [PubMed:10086783].
   Google Scholar
• Masaki Y, Nakajima A, Iwao H, et al. Japanese variant of multicentric castleman’s disease associated with serositis and thrombocytopenia–a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop. 2013;53:79–85. [PubMed:23801138].
   Google Scholar
• Gherardi RK, Belec L, Fromont G, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood. 1994;83:2587–2593. [PubMed:8167341].
   Google Scholar
• Lee M, Hirokawa M, Matuoka S, et al. Multicentric Castleman’s disease with an increased serum level of macrophage colony-stimulating factor. Am J Hematol. 1997;54:321–323. [PubMed:9092689].
   Google Scholar
• Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3:1202–1216. [PubMed:4031967].
   Google Scholar
• Lachant NA, Sun NC, Leong LA, et al. Multicentric angiofollicular lymph node hyperplasia (Castleman’s disease) followed by Kaposi’s sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol. 1985;83:27–33. [PubMed:3871303].
   Google Scholar
• Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood. 2000;96:2069–2073. [PubMed:10979949].
   Google Scholar
• Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman’s disease. Am J Hematol. 2012;87:997–1002. [PubMed:22791417].
   Google Scholar
• Ganti AK, Pipinos I, Culcea E, et al. Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am J Hematol. 2005;79:206–210. [PubMed:15981232].
   Google Scholar
• Guihot A, Couderc LJ, Agbalika F, et al. Pulmonary manifestations of multicentric Castleman’s disease in HIV infection: a clinical, biological and radiological study. Eur Respir J. 2005;26:118–125. [PubMed:15994398].
   Google Scholar
• Mian H, Leber B. Mixed variant multicentric Castleman disease treated with rituximab: case report. J Pediatr Hematol Oncol. 2010;32:622. [PubMed:20921905].
   Google Scholar
• Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood. 2009;113:4521–4524. [PubMed:19224759].
   Google Scholar
• Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol. 2011;29:2481–2486. [PubMed:21555697].
   Google Scholar
• Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric Castleman’s disease. Am J Hematol. 2008;83:498–503. [PubMed:18260115].
   Google Scholar
• Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman’s disease using rituximab. Eur J Haematol. 2006;76:119–123. [PubMed:16405432].
   Google Scholar
• Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol. 2012;24:495–505. [PubMed:22729151].
   Google Scholar
• Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124:3544–3552. [PubMed:25331113].
   Google Scholar
• Fukumoto H, Kanno T, Hasegawa H, et al. Pathology of Kaposi’s Sarcoma-associated herpesvirus infection. Front Microbiol. 2011;2:175. [PubMed:21904536].
   Google Scholar
• Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330:602–605. [PubMed:8302342].
   Google Scholar
• Foussat A, Fior R, Girard T, et al. Involvement of human interleukin-6 in systemic manifestations of human herpesvirus type 8-associated multicentric Castleman’s disease. AIDS. 1999;13:150–152. [PubMed:10207568].
   Google Scholar
• Chen KT. Multicentric Castleman’s disease and Kaposi’s sarcoma. Am J Surg Pathol. 1984;8:287–293. [PubMed:6711739].
   Google Scholar
• Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116:3627–3634. [PubMed:20644113].
   Google Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966–974. [PubMed:25042199].
   Google Scholar
• Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61. [PubMed:10607684].
   Google Scholar
• Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147:836–839. [PubMed:18087054].
   Google Scholar
• Ohsugi Y, Tsuchimoto N. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman’s disease]. Nihon Yakurigaku Zasshi. 2005;126:419–425. [PubMed:16462093].
   Google Scholar
• Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151–3171. [PubMed:15094765].
   Google Scholar
• Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16:1472–1487. [PubMed:12080086].
   Google Scholar
• Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35:7S–14S. [PubMed:12742462].
   Google Scholar
• Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–1323. [PubMed:15800227].
   Google Scholar
• Gasperini P, Tosato G. Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma. Leukemia. 2009;23:1867–1874. [PubMed:19554030].
   Google Scholar
• Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood. 2007;109:2165–2173. [PubMed:17082322].
   Google Scholar
• Nichols LA, Adang LA, Kedes DH. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoS One. 2011;6:e14535. [PubMed:21264294].
   Google Scholar
• Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220–226. [PubMed:26805758].
   Google Scholar
• Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686–692. [PubMed:27084250].
   Google Scholar